Comparative Evaluation of the Effects of Amlodipine, Cilnidipine, and Calcium Channel Antagonists on the QT Interval in Hypertensive Patients
Authors/Creators
- 1. Junior Resident-3, Department of Pharmacology, S.M.M.H. Government Medical College, Saharanpur, U.P.
- 2. Professor, Department of Pharmacology, S.M.M.H. Government Medical College, Saharanpur, U.P.
- 3. Associate Professor, Department of Pharmacology, S.M.M.H. Government Medical College, Saharanpur, U.P.
- 4. Assistant Professor, Department of Pharmacology, S.M.M.H. Government Medical College, Saharanpur, U.P.
Description
Background: 12-lead electrocardiography measures the length of the QT interval, which is a marker of myocardial repolarization and is frequently used to characterize cardiac abnormalities, identify cardiac toxicity, and assess drug safety. After controlling for the impact of other risk variables, the QT interval in hypertension can predict the risk of both coronary events and cardiovascular death. Calcium channel blockers are the first-line medication for treating hypertension, according to the American Heart Association and JNC VIII. Numerous investigations have shown that amlodipine and cilnidipine, when taken at comparable doses, have an equipotent antihypertensive impact. Aims of this study to compare and evaluate the effects of calcium channel antagonists amlodipine and cilnidipine on QT interval among hypertensive patients. Methods: During that time, 129 patients in all were screened, evaluated, and recruited as study participants. Following enrollment, the patients were split into one category: hypertensive patients (n = 80). Amlodipine (2.5–10 mg) or cilnidipine (5–20 mg) with or without an angiotensin receptor blocker (ARB) was administered to a subset of patients, and (2) hypertensive patients with managed diabetes (n = 49) Selected participants were given antidiabetic medicine combined with either amlodipine (2.5–10 mg) or cilnidipine (5–20 mg), with or without an ARB. QT interval/√ (relative risk [RR] interval), where RR interval = 60/heart rate, is calculated using Bazett’s method (the most often used), with normal QTc ≤440 ms. Patients with hypertension had their QT intervals tested both at baseline and after a year of medication. Results: Although there was no therapeutic significance, there was a very significant decrease in QTc with cilnidipine therapy and a significant increase with amlodipine medication. Extremely significant and clinically important differences between amlodipine and cilnidipine were observed while comparing their effects. Conclusion: According to this study, cilnidipine is a better option than amlodipine for patients with a lengthy QT interval since it shortens the QTc interval.
Abstract (English)
Background: 12-lead electrocardiography measures the length of the QT interval, which is a marker of myocardial repolarization and is frequently used to characterize cardiac abnormalities, identify cardiac toxicity, and assess drug safety. After controlling for the impact of other risk variables, the QT interval in hypertension can predict the risk of both coronary events and cardiovascular death. Calcium channel blockers are the first-line medication for treating hypertension, according to the American Heart Association and JNC VIII. Numerous investigations have shown that amlodipine and cilnidipine, when taken at comparable doses, have an equipotent antihypertensive impact. Aims of this study to compare and evaluate the effects of calcium channel antagonists amlodipine and cilnidipine on QT interval among hypertensive patients. Methods: During that time, 129 patients in all were screened, evaluated, and recruited as study participants. Following enrollment, the patients were split into one category: hypertensive patients (n = 80). Amlodipine (2.5–10 mg) or cilnidipine (5–20 mg) with or without an angiotensin receptor blocker (ARB) was administered to a subset of patients, and (2) hypertensive patients with managed diabetes (n = 49) Selected participants were given antidiabetic medicine combined with either amlodipine (2.5–10 mg) or cilnidipine (5–20 mg), with or without an ARB. QT interval/√ (relative risk [RR] interval), where RR interval = 60/heart rate, is calculated using Bazett’s method (the most often used), with normal QTc ≤440 ms. Patients with hypertension had their QT intervals tested both at baseline and after a year of medication. Results: Although there was no therapeutic significance, there was a very significant decrease in QTc with cilnidipine therapy and a significant increase with amlodipine medication. Extremely significant and clinically important differences between amlodipine and cilnidipine were observed while comparing their effects. Conclusion: According to this study, cilnidipine is a better option than amlodipine for patients with a lengthy QT interval since it shortens the QTc interval.
Files
IJPCR,Vol16,Issue12,Article164.pdf
Additional details
Dates
- Accepted
-
2024-11-26
Software
- Repository URL
- http://impactfactor.org/PDF/IJPCR/16/IJPCR,Vol16,Issue12,Article164.pdf
- Development Status
- Active
References
- 1. Krishnadas KV. Text Book of Medicine. 4th ed., Vol 2. New Delhi: Jaypee Brothers; 2004; 651. 2. Rung MS, Greganti AM. Netter's Internal Medicine. USA: Icon Learning Systems LLC; 2003. p. 127-8. 3. Saseen JJ. Hypertension, applied therapeutics In: Koda-Kimble MA, Young LY, Alldredge BK, editors. The Clinical use of Drugs. 9th ed. Baltimore, MD: Lippincott Williams & Wilkins; 2009. p. 13-8. 4. Mozos I, Serban C. The relation between QT interval and T-wave variables in hypertensive patients. J Pharm BioalliedSci 2011;3:339-44. 5. Kang YJ. Cardiac hypertrophy: A risk factor for QT-prolongation and cardiac sudden death. ToxicolPathol 2006;34:58-66. 6. Klimas J, Vaja V, Vercinska M, Kyselovic J, Krenek P. Discrepant regulation of QT (QTc) interval duration by calcium channel blockade and angiotensin converting enzyme inhibition in experimental hypertension. Basic ClinPharmacol Toxicol 2012;111:279-88. 7. Baumert M, Schlaich MP, Nalivaiko E, Lambert E, Sari CI, Kaye DM, et al. Relation between QT interval variability and cardiac sympathetic activity in hypertension. Am J Physiol Heart CircPhysiol 2011;300:H1412-7. 8. Magnano AR, Holleran S, Ramakrishnan R, Reiffel JA, Bloomfield DM. Autonomic nervous system influences on QT interval in normal subjects. J Am CollCardiol 2002;39:1820-6. 9. Darbar D, Fromm MF, Dellorto S, Roden DM. Sympathetic activation enhances QT prolongation by quinidine. J Cardiovasc Electrophysiol 2001;12:9-14. 10. Antzelevitch C, Shimizu W. Cellular mechanisms underlying the long QT syndrome. CurrOpinCardiol 2002;17:43-51. 11. Noda T, Takaki H, Kurita T, Suyama K, Nagaya N, Taguchi A, et al. Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome. Eur Heart J 2002;23:975-83. 12. Schwartz PJ, Priori SG, Cerrone M, Spazzolini C, Odero A, Napolitano C, et al. Left cardiac sympathetic denervation in the management of high-risk patients affected by the long-QT syndrome. Circulation 2004;109:1826-33. 13. Porthan K, Viitasalo M, Hiltunen TP, Vaananen H, Dabek J, Suonsyrja T, et al. Short-term electrophysiological effects of losartan, bisoprolol, amlodipine, and hydrochlorothiazide in hypertensive men. Ann Med 2009;41:29-37. 14. Milovanović B, Trifunović D, Milićević N, Vasić K, Krotin M. The significance of amlodipine on autonomic nervous system adjustment (ANSA method): A new approach in the treatment of hypertension. SrpArhCelokLek 2009;137:371-8. 15. Zhao Z, Yuan Z, Ji Y, Wu Y, Qi Y. Left ventricular hypertrophyamplifies the QT, and Tp-e intervals and the Tp-e/QT ratio of left chest ECG. J Biomed Res 2010;24:69-72. 16. Mozos I, Costea C. The QT interval and left ventricular hypertrophy in essential hypertension. In: Sobieszczanska M, Jagielski J, Macfarlane PW, editors. Electrocardiology. Proceedings of the 36th International Congress on Electro Cardiology. Wroclaw, Poland: JAKS Publishing Company; 2010. p. 203-9. 17. Oikarinen L, Nieminen MS, Viitasalo M, Toivonen L, Jern S, Dahlöf B, et al. QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: The losartan intervention for endpoint reduction in hypertension study. Hypertension 2004;43:1029-34. 18. Hancock EW, Deal BJ, Mirvis DM, Okin P, Kligfield P, Gettes LS. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: Part V: Electrocardiogram changes associated with cardiac chamber hypertrophy. Circulation 2009;19:e251-61. 19. Xu X, Rials SJ, Wu Y, Salata JJ, Liu T, Bharucha DB, et al. Left ventricular hypertrophy decreases slowly but not rapidly activating delayed rectifier potassium currents of epicardial and endocardialmyocytes in rabbits. Circulation 2001;103:1585-90. 20. Takahara A, Nakamura Y, Wagatsuma H, Aritomi S, Nakayama A, Satoh Y, et al. Longterm blockade of L/N-type ca (2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart. Br J Pharmacol 2009;158:1366-74.21. Yu H, Gao J, Wang H, Wymore R, Steinberg S, McKinnon D, et al. Effects of the reninangiotensin system on the current Ito in epicardial and endocardial ventricular myocytes from the canine heart. Circ Res 2000;86:1062-8. 22. Domenighetti AA, Boixel C, Cefai D, Abriel H, Pedrazzini T. Chronic angiotensin II stimulation in the heart produces an acquired long QT syndrome associated with IK1 potassium current down regulation. J Mol Cell Cardiol 2007;42:63-70. 23. Wang YH, Shi CX, Dong F, Sheng JW, Xu YF. Inhibition of the rapid component of the delayed rectifier potassium current in ventricular myocytes by angiotensin II via the AT1 receptor. Br J Pharmacol 2008;154:429- 39. 24. Takemori K, Ishida H, Dote K, Yamamoto K, Ito H. Prophylactic effects of an N-and L-type ca2+ antagonist, cilnidipine, against cardiac hypertrophy and dysfunction in stroke-prone, spontaneously hypertensive rats. Can J PhysiolPharmacol 2005;83:785-90. 25. Konda T, Enomoto A, Takahara A, Yamamoto H. Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. Biol Pharm Bull 2006;29:933-7. 26. Konda T, Enomoto A, Aritomi S, Niinuma K, Koganei H, Ogawa T, et al. Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm. Am J Nephrol 2009;30:155-61. 27. Aritomi S, Nogi Y, Koganei H, Mitsui A, Konda T, Yoshimura M. The role of N-type calcium channels in regulating aldosterone secretion in H295R human adrenocortical cells. J Am SocNephrol 2007;18:155A.